Ludovic Helfgott/LinkedIn
Nov 15, 2025, 15:45
Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
Ludovic Helfgott, Executive Vice President, Product and Portfolio Strategy at Novo Nordisk, shared a post on LinkedIn:
“New paper in The Lancet Group today. Researchers have analysed Novo Nordisk product data in obesity and cardiovascular disease and the results suggest that a reduction of major adverse cardiovascular events in people with overweight or obesity is independent of baseline weight and weight loss.
These findings again support our strategy to reduce the risk of cardiovascular events for the hundreds of millions of people living with overweight or obesity and cardiovascular disease and promote their long-term health.”
Stay updated with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera